Forum Topic Vaccines
  • Conversation: A COVID-19 Vaccine candidate

    • October 3, 2020 1:50 AM BST
    • A COVID-19 Vaccine candidate

      Interesting points from #modena's COVID-19-mRNA-vaccine-candidate tested in older and elderly adults as unveiled on September 29, 2020:'Both the 25 µg and 100 µg dose levels of mRNA-1273 were generally well-tolerated, with no serious adverse events reported through Day 57.''Immune response were dose-dependant with 100 µg dose eliciting higher binding and neutralizing antibody titters, ...''The most common solicited adverse events were headache, fatigue, myalgia, chills, and pain at the injection site, the majority of which were mild-to-moderate in severity and self-limited duration.''Local and systemic reactogenicity were more common and more frequently moderate in severity after the second dose.''Participants will continue to be followed through 13-months to allow for longer assessment of vaccine-related adverse events.''Neutralizing antibody titers and T cell responses in 56-70 and 71+ age cohorts were consistent with those reported in younger adults.''The U.S. government has agreed to purchase 100 million doses of mRNA-1273, with an option to purchase an additional 400 million doses.' End quoteCredit:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel